Artgen Biotech PJSC (MIC:ABIO) Accounts Payable: ₽147 Mil (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIC:ABIO Artgen Biotech PJSC MIC:ABIO
17 GF Score
Price ₽44.46
View Full Analysis

What is Artgen Biotech PJSC Accounts Payable?

Artgen Biotech PJSC MIC:ABIO +0.50% 17 Accounts Payable is ₽147 Mil as of Jun. 2023. GuruFocus rates MIC:ABIO with a GF Score™ of 17/100.

Artgen Biotech PJSC's Accounts Payable for the quarter that ended in Jun. 2023 was ₽147 Mil.

Artgen Biotech PJSC's quarterly Accounts Payable declined from Jun. 2022 (₽111 Mil) to Dec. 2022 (₽67 Mil) but then increased from Dec. 2022 (₽67 Mil) to Jun. 2023 (₽147 Mil).

Artgen Biotech PJSC's annual Accounts Payable increased from Dec. 2020 (₽97 Mil) to Dec. 2021 (₽102 Mil) but then declined from Dec. 2021 (₽102 Mil) to Dec. 2022 (₽67 Mil).

Artgen Biotech PJSC Accounts Payable Related Terms

Artgen Biotech PJSC Accounts Payable Historical Data

* Premium members only.

The historical data trend for Artgen Biotech PJSC's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artgen Biotech PJSC Accounts Payable Chart

Artgen Biotech PJSC Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 121.52 82.64 97.35 102.32 66.84

Artgen Biotech PJSC Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 89.76 102.32 111.11 66.84 146.62
MIC:ABIO
17GF Score
Artgen Biotech PJSC MIC:ABIO
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Artgen Biotech PJSC Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of ₽147 Mil mean?
Artgen Biotech PJSC (MIC:ABIO) has a Accounts Payable of ₽147 Mil as of Jun. 2023. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Artgen Biotech PJSC and its competitors.
Is Artgen Biotech PJSC's Accounts Payable too high?
Artgen Biotech PJSC's current Accounts Payable is ₽147 Mil. Overall, Artgen Biotech PJSC has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Artgen Biotech PJSC's Accounts Payable compare to VRTX and REGN?
Artgen Biotech PJSC's Accounts Payable of ₽147 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Artgen Biotech PJSC and its competitors. Artgen Biotech PJSC's current Accounts Payable is ₽147 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artgen Biotech PJSC stock overvalued right now?
Artgen Biotech PJSC (MIC:ABIO) has a current Accounts Payable of ₽147 Mil. The current Accounts Payable is ₽147 Mil. Artgen Biotech PJSC's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Artgen Biotech PJSC (MIC:ABIO), the current Accounts Payable is ₽147 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Artgen Biotech PJSC Business Description

Address Prospect of the 60th Anniversary, Moscow, RUS, 117036
Artgen Biotech PJSC is a biotechnology company. It is engaged in the drug discovery, research and development and marketing of proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy, and biopharmaceutics. The company has developed Neovasculgen, which is a gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia and also develops SPRS therapy which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.
17GF Score

Get the complete analysis for MIC:ABIO

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₽44.46
Price